Workflow
百花医药(600721) - 2021 Q3 - 季度财报
BHCBHC(SH:600721)2021-10-26 16:00

Financial Performance - The company's operating revenue for the third quarter reached ¥64,582,728.22, representing a year-on-year increase of 470.95%[3] - The net profit attributable to shareholders was ¥4,945,568.20, reflecting a significant increase of 196.08% compared to the same period last year[3] - The basic earnings per share (EPS) for the quarter was ¥0.0132, up 189.19% year-on-year[3] - The net profit attributable to shareholders increased by 231.07% to CNY 54.89 million, compared to a net loss of CNY 41.88 million in the same period last year, primarily due to increased sales and gains from equity transfer and debt restructuring[8] - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 105.85% to CNY 5.96 million, compared to a net loss of CNY 10.19 million in the same period last year, mainly driven by increased sales[8] - Basic earnings per share rose by 237.37% to CNY 0.1463, compared to a loss of CNY 0.1065 in the same period last year, reflecting the increase in sales[8] - Operating profit for the first three quarters of 2021 was ¥47,478,367.11, compared to a loss of ¥101,253,622.51 in the first three quarters of 2020, indicating a turnaround in profitability[17] - Net profit for the first three quarters of 2021 was ¥54,931,343.97, a substantial improvement from a net loss of ¥41,881,540.74 in the same period of 2020[17] Assets and Liabilities - Total assets at the end of the reporting period were ¥966,826,158.11, a decrease of 0.81% from the end of the previous year[4] - Total liabilities decreased to ¥287,729,927.25 as of September 30, 2021, from ¥350,519,430.13 at the end of 2020, reflecting a reduction of approximately 17.9%[15] - The company's total assets as of September 30, 2021, amounted to ¥966,826,158.11, slightly down from ¥974,684,317.02 at the end of 2020[15] - The company's equity attributable to shareholders increased to ¥674,159,273.98 as of September 30, 2021, up from ¥619,263,889.76 at the end of 2020, marking an increase of about 8.9%[15] Cash Flow - Cash flow from operating activities showed a net outflow of ¥7,698,340.41, a decline of 484.50% compared to the previous year[3] - The net cash flow from investing activities decreased by 135.24% to a net outflow of CNY 11.68 million, compared to a net inflow of CNY 33.15 million in the same period last year, mainly due to increased cash expenditures for purchasing bank wealth management products[8] - The net cash flow from financing activities increased by 290.72% to CNY 1.27 million, compared to a net outflow of CNY 0.66 million in the same period last year, primarily due to bank loans from the subsidiary[8] - The net cash flow from operating activities for the first three quarters of 2021 was -7,698,340.41 RMB, compared to 2,002,156.36 RMB in the same period of 2020, indicating a decline in operational performance[20] - The company reported a cash balance of 27,503,292.51 RMB at the end of the reporting period, a decrease from 85,610,987.20 RMB at the end of the same period in 2020[21] - The company experienced a net decrease in cash and cash equivalents of -18,112,147.95 RMB, contrasting with an increase of 34,487,824.38 RMB in the same period of 2020[21] Research and Development - Research and development expenses increased to ¥3,253,800, representing a full increase compared to the same period last year, driven by innovation drug research[7] - Research and development expenses for the first three quarters of 2021 were reported at ¥3,253,778.41, indicating ongoing investment in innovation[17] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10,503[10] - The largest shareholder, Xinjiang Hualing Industry and Trade Group Co., Ltd., holds 21.20% of the shares, totaling 79,525,087 shares[10] - The company implemented an employee stock option incentive plan, granting 12.1 million stock options to 162 participants[12] Sales and Expenses - The company’s sales expenses increased by 30.48% to ¥437,630, primarily due to hiring more sales personnel to expand market reach[7] - The company's total operating costs for the first three quarters of 2021 were ¥166,930,022.40, down from ¥186,031,966.71 in the same period of 2020, reflecting a cost reduction strategy[17]